Navigation Links
Patent Granted for Simbionix Procedure Rehearsal Studio™
Date:8/10/2011

CLEVELAND, Ohio, August 10, 2011 /PRNewswire/ --

Simbionix USA Corporation, the world's leading provider of medical simulation training and education products for medical professionals and the healthcare industry, is pleased to announce it has been granted a patent in the UK for its innovative PROcedure Rehearsal Studio.

The PROcedure Rehearsal Studio™ is a first in industry product, allowing clinicians to create patient specific 3D and 4D anatomical models based on a patient's imaging data, such as CT, for the purpose of simulating and planning endovascular procedures. The patent was granted on Simbionix's proprietary technology used in order to simulate an image guided angioplasty procedure based on input from a patient's 3D medical image, allowing a hands-on planning and rehearsal experience as well as providing physicians with unlimited generation of unique clinical case studies and the ability to better demonstrate a complex clinical procedure to their patients.

Earlier this year, the PROcedure Rehearsal Studio software was market cleared in the United States, intended for use as a software interface and image segmentation system for the transfer of imaging data from a medical scanner to an output file. It is also intended as pre-operative software for simulating and evaluating surgical treatment options. Unique to the Simbionix simulation systems, the 3D segmentation model can be exported to the Simbionix ANGIO Mentor™ Simulator practice environment. The results are an advanced method of creating an ever expanding library of modules for training and post-operative debriefing.  

"This addition to the company's comprehensive IP portfolio is evidence to the uniqueness and quality of Simbionix's products and exceptional development team," said Simbionix CFO, Mr. Boaz Tal. "Technologically advanced medical education solutions are becoming more accepted and are regularly integrated into medical training programs. The patented PROcedure Rehearsal Studio allows for the integration of medical imaging into training, stregthening the link between the clinical and training. Having been granted the patent is an additional sign of recognition for the Simbionix comprehensive line of products, which provide innovative solutions to advance medical performance and ensure patient safety."

About Simbionix USA Corporation  

Simbionix is the world's leading provider of simulation and training products for medical professionals and the healthcare industry. Founded in 1997, the company is committed to delivering high quality products, advancing clinical performance and optimizing procedural outcomes.

For more information on Simbionix, visit http://www.simbionix.com

Contact: Rebecca Zitter, +1-216-229-2040 - ext. 128, rebecca@simbionix.com



'/>"/>
SOURCE Simbionix USA Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Echo Therapeutics Announces Multiple Patents and Trademark Grants
2. Hepatitis B Vaccine - Comprehensive Patent Search
3. Silence Therapeutics Receives Notice of Allowance for New U.S. Patent Covering Novel Small Interfering RNA (siRNA) Delivery Technology
4. Mylan Announces U.S. PTO Intends to Reissue Two Perforomist® Patents to Dey Pharma
5. U.S. Court of Appeals Affirms Validity of Lillys Strattera Patent
6. Watson Confirms JALYN™ Patent Challenge
7. BioMedix™ Receives Patent for Its Innovative Collaborative Care Business Method
8. Kuros Announces Allowance of US Patent for the Local Application of Parathyroid Hormone (PTH) for Bone Healing
9. Amgen Resolves G-CSF Patent Litigation With Teva
10. Convergen LifeSciences Announces Patent Award
11. Neuralstem Announces Notice of Allowance for Two Additional Neurogenic Compound Patents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... -- One of Australia,s successful biotechnology scientists, ... new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). ... list on the ASX. Noxopharm is a clinic-ready company ... Phase 1 clinical study later this year. ... biggest problems facing cancer patients - the ability of cancers to ...
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... The OSHA ... Training Institute Education Center headquartered in Northern California, has issued an important reminder ... at their worksites. Employers with workers exposed to high temperatures should establish ...
(Date:6/27/2016)... ... , ... "FCPX editors can now reveal their media with growing colorful split ... Austin - CEO of Pixel Film Studios. , ProSlice Color brings the split ... now reveal the media of their split screens with growing colorful panels. , ProSlice ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... mental health professionals, announced today its affiliation with Tennessee Counseling Association. ... to the network of the Tennessee Counseling Association, adding exclusive benefits and promotional ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... its strategic partnership with Connance, a healthcare industry leader providing predictive analytics ... proprietary technology combine to provide health systems, hospitals and ambulatory surgical centers ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... cutting edge technology to revolutionize the emergency ambulance transport experience for the millions ... aware of how Uber has disrupted the taxi industry through the use of ...
Breaking Medicine News(10 mins):